Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC - Takeaways - MDSpire
Clinical Guidelines

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

In the final analysis of the phase III EORTC 1333/PEACE-3 trial, with a median follow-up of 58 months, the addition of radium-223 to the androgen receptor inhibitor enzalutamide significantly prolonge...

  • By

  • Caroline Helwick

  • May 14, 2026

  • 8 min

Share

  • 1

    The trial evaluated the addition of radium-223 to enzalutamide.

  • 2

    Significant overall survival benefit was observed (5.6 months).

  • 3

    Treatment reduced prostate cancer mortality by 24%.

  • 4

    Common toxicity: hypertension (36% in both groups).

  • 5

    Final analysis confirmed earlier benefits in radiographic progression-free survival.

  • 6

    Study limitations noted, especially in contemporary patient applicability.

  • 7

    Study involved 446 patients with bone metastases.

  • 8

    Importance of bone-protective agents emphasized for patients receiving radium-223.

Original Source(s)

Combination Enzalutamide and Radium-223 Extends Overall Survival in Bone-Dominant mCRPC

  • by Caroline Helwick

  • May 14, 2026

Related Content

Does the Timing of Immunotherapy Administration Affect Outcomes in Advanced Cancers?

A systematic review and meta-analysis found that early time-of-day immunotherapy was associated with improved survival outcomes in patients with advanced cancers, with the association appearing to be ...

Lack of Research in Understanding the Global Population of Childhood Cancer Survivors Leads to Gaps in Care and Cures

Each year, globally, about 400,000 children and adolescents aged between 0 and 19 years are diagnosed with cancer; over 100,000 die from the disease, with most of those cases, over 80%, and deaths occ...

New Clues in Hodgkin Lymphoma Biology

Transcriptome analysis highlights diagnostic targets and immune evasion pathways

  • May 14, 2026

  • 2 min